RayzeBio

We are building a vertically integrated radiopharmaceutical therapeutics company with our lead program in a Phase 3 clinical trial. We are building on the century old experience of radiation therapy by harnessing the power of radioisotopes and delivering them intravenously in a targeted manner directly to solid tumors, including metastatic disease, to selectively kill cancer cells. RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting. RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors. We believe we have established a leadership position in the emerging radiopharmaceutical therapeutics modality through a product-centric approach and have created a pipeline of multiple drug and development candidates in therapeutic areas with significant market opportunities. External beam radiation therapy is a proven approach to treating many cancers and is typically administered by an external beam of high energy rays. In contrast, radiopharmaceutical therapy (RPT) delivers radioisotopes to tumors intravenously. We believe RPT represents one of the most promising new modalities for the treatment of solid tumors.